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Arginylation is an emerging posttranslational modifi-
cation mediated by Arg-tRNA-protein-transferase
(ATE1). It is believed that ATE1 links Arg solely to
the N terminus of proteins, requiring prior proteolysis
or actionbyMet-aminopeptidases to expose theargi-
nylatedsite.Here,we tested thepossibility ofArg link-
age tomidchain siteswithin intact protein targets and
found that many proteins in vivo are modified on the
side chains of Asp and Glu by unconventional chem-
istry that targets the carboxy rather than the amino
groups at the target sites. Such arginylation appears
to be functionally regulated, and it can be directly
mediated by ATE1, in addition to the more conven-
tional ATE1-mediated linkage of Arg to the N-terminal
alpha amino group. This midchain arginylation im-
plies an unconventional mechanism of ATE1 action
that likely facilitates its major biological role.
INTRODUCTION
Arginylation is an emerging posttranslational modification medi-
ated by arginyltransferase (ATE1) that transfers Arg from the Arg-
tRNA on to proteins. Recent studies have demonstrated an
essential role of this modification in key physiological events
(Carpio et al., 2013; Karakozova et al., 2006; Lo´pez Sambrooks
et al., 2012; Saha and Kashina, 2011; Varshavsky, 1997; Zhang
et al., 2012) and identified a large number of arginylated proteins
in vivo (Wong et al., 2007), confirming its important biological
role. Despite its significance, very little is known about the mech-
anisms of ATE1-mediated Arg linkage to proteins. Earlier studies
postulated that ATE1 attaches Arg to the N-terminally exposed
amino group of a polypeptide chain via a peptide bond, reminis-
cent of the peptide elongation steps on the ribosome. In vitro and
in vivo studies show that ATE1 preferentially targets the N-termi-
nally exposed residues with acidic side chains (Asp and Glu) in
proteins, produced via limited proteolysis or N-terminal prepro-
cessing by specific types of aminopeptidases. However, veryChemistry & Biology 21, 3fewN-terminally arginylated proteins have been identified in vivo,
despite the fact that overall estimates suggest that a large per-
centage of the proteome may undergo arginylation (Wong
et al., 2007). These results leave open the possibility that arginy-
lation may also occur at internal sites within intact proteins,
which have not been commonly considered during previous
identification strategies.
A recent study identified an in vivo form of the regulatory pep-
tide neurotensin, modified by arginylation on a side chain of an
internal Glu via an amide bondwith the amino group of Arg (Eriste
et al., 2005). Such Arg linkage at the acidic side chain of a mid-
chain residue can account for additional arginylated protein sub-
strates in vivo. However, modification of the acidic side chains of
internal Asp and Glu residues, at a first glance, would require
very different chemistry than ‘‘conventional’’ arginylation chem-
istry of N-terminal Asp/Glu, leaving open the questions of
whether this alternative modification indeed targets proteins
in vivo and whether it can be performed by ATE1.
Here, we report that many proteins in vivo are modified on the
side chains of Asp and Glu and that this modification can be
directly mediated by ATE1, in addition to its more conventional
linkage by N-terminal alpha amino group. This type of arginyla-
tion likely facilitates the major biological role of arginylation in
regulation of intact proteins during key physiological processes.
RESULTS
Arginylation In Vivo Can Occur on Midchain Asp and Glu
To test the possibility that addition of Arg to proteins can happen
at internal sites and not on their N termini, we performed mass
spectrometry analysis of cell extracts and subcellular structures
described in our prior studies (affinity-enriched cell and embryo
extracts [Wang et al., 2011], nuclear extracts [Saha et al., 2011],
platelets, and myofibril preparations [Kurosaka et al., 2012]), to
look for addition of Arg to any Asp, Glu, and Lys (the only three
residues that can theoretically accept Arg directly on their side
chains), using the search algorithms commonly applied to post-
translational modifications. Although Lys searches did not yield
any hits,we foundanumber of previously unidentified siteswhere
Argwas added tomidchain Asp andGlu (Figure 1A; Table 1; Sup-
plemental Dataset and Tables S1 and S2 available online).31–337, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 331
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Table 1. Protein Sites Arginylated In Vivo on the Side Chains of Asp and Glu
Accession Code Source Name Modified Residue
NP_033738.1 myofibrils actin, alpha cardiac muscle 1 E102, E169
NP_033736.1 platelets actin, alpha skeletal muscle E85
NP_033739.1 platelets actin, cytoplasmic 2 E167
NP_150371.4 myofibrils alpha-actinin-2 E512
NP_036073.1 platelets dual specificity mitogen-activated protein kinase kinase 6 E307
NP_031894.1 myofibrils dystrophin E2570
NP_031953.1 platelets emerin D127
NP_666232.2 platelets gelsolin precursor E261, E264
NP_001124340.1 platelets lysyl-tRNA synthetase isoform 1 D403
NP_081797.1 platelets minor histocompatibility protein HA-1 isoform 2 D826
NP_034997.2 myofibrils myomesin-1 isoform 1 E1220
NP_034989.1 myofibrils myosin light chain 3 E121
NP_034986.1 myofibrils myosin-6 E1030, E1491, D1654
NP_542766.1 myofibrils myosin-7 E1578
NP_071855.2 platelets myosin-9 isoform 1 E1073
NP_032138.3 platelets Rab GDP dissociation inhibitor beta D34
NP_035372.2 platelets RAS guanyl-releasing protein 2 E408
NP_035782.3 myofibrils titin isoform N2-A D1068, D14177, E14547
NP_033473.1 platelets tubulin alpha-4A chain (Mus musculus) E90
See Table S1 for the list of sites shared by homologous isoforms of these proteins.
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the vicinity of the arginylation site, the frequency of occurrence
of specific amino acid residues around the arginylation site,
compared to their overall frequency in the identified proteins,
showed a bias toward His and Pro and against Cys (never found
within five residues of the arginylated sites and poorly repre-
sented within up to 20 flanking residues) (Table S3).
Midchain Asp Arginylation Is Mediated by ATE1
To test whether ATE1 can directly mediate Arg addition to the
side chains of Asp or Glu, we used a test peptide corresponding
to the N terminus of ATE1’s natural substrate, beta actin (Karako-
zova et al., 2006), containing an N-terminal Arg covalently linked
into thepeptidebackbone (RDDIAALVVDNGSGMCK; Figure1B).
We reasoned that such a peptide would be more likely to facili-
tate ATE1 recognition than a randomly selected peptide but
should constitute an unfavorable N-terminal target for ATE1,
since it already contains an N-terminally linked Arg. In agreement
with these predictions, in vitro arginylation of this peptide by
purified ATE1-1 (Wang et al., 2011) resulted in its arginylation
at Asp9 (Figure 1B)—the site where the only possible Arg addi-
tion can occur via the acidic side chain of Asp. This reaction,
similarly to the N-terminal arginylation, occurred with higher
efficiency in the presence of ATE1-1 and ATE1-2, rather than
ATE1-3 and ATE1-4 (Wang et al., 2011) (Figure 2A). Control ex-Figure 1. Arginylation on Side Chains of Acidic Residues In Vivo and In
(A) Mass spectrum of a naturally occurring arginylated peptide, with Arg added to t
residue marked by +156 (a mass of Arg).
(B) Mass spectrum of a standard peptide, enzymatically arginylated on the side c
marked by +166 (a mass of stable isotope labeled [13C,15N]-Arg used in the exp
See also Tables 1, S1, and S2.
Chemistry & Biology 21, 3periments confirmed that this side chain arginylation is tRNA
dependent, since no Arg incorporation into this peptide could
be seen in the absence of tRNA (Figure S1).
Both the Amino and Carboxyl Groups of the N-Terminal
Residue Facilitate Arginylation
Our finding that ATE1 can add Arg to the side chain of internal
residues raises a possibility that, unlike previously believed,
ATE1 always targets the carboxyl group of Asp and Glu, even
when they are N-terminally exposed. To address this possibility,
we tested the requirement of the amino and carboxyl groups of
the N-terminal acidic residue by analyzing synthetic peptides
derived from the actin’s N-terminal sequence without the inter-
nal Asp residues (DIAALVHSSGMC; termed DN in Figure 2B),
intact or chemically modified by the addition of a methyl group
to block the N-terminal amino group of Asp (DN-Me) or an allyl
ester (All) group to block the carboxyl group of the Asp side
chain (DN-All). Comparison of the arginylation efficiency of
these three peptides showed that, while DN was a highly effi-
cient ATE1-1 substrate, blocking either the amino group or
the carboxyl group of the N-terminal Asp in this peptide in-
hibited arginylation (Figure 2B). While a small amount of Arg
incorporation was still seen in the DN-All peptide, we detected
no arginylated DN-All by MALDI-TOF or tandem mass spec-
trometry (MS/MS), suggesting that this Arg incorporation couldVitro
he side chain of Asp. Peptide sequence is indicated on top, with the arginylated
hain of Asp. Peptide sequence is indicated on top, with the arginylated residue
eriment). Numbers indicate the masses of b (red) and y (blue) ions.
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Figure 2. Characterization of Side Chain and N-Terminal Arginy-
lation
(A) Normalized incorporation of [3H]-Arg into a standard peptide corre-
sponding to the N-terminal sequence of beta actin mediating N-terminal
arginylation (DDIAALVVDNGSGMCK; left) and the same peptide with an
N-terminal Arg inserted into the sequence to facilitate side chain arginylation
(RDDIAALVVDNGSGMCK, right) with four ATE1 isoforms. Error bars represent
SEM (n = 3 for DDIAALVVDNGSGMCK and 4 for RDDIAALVVDNGSGMCK).
(B) N-terminal arginylation requires the presence of both a carboxyl group and
an amino group. Normalized incorporation of [3H]-Arg into a synthetic DN
peptide (containing N-terminal Asp and no internal arginylation sites; see
Results) is greatly inhibited when the amino group of the N-terminal Asp is
modified with a methyl group (DN-Me) or when the carboxyl group is an allyl
ester (DN-All). Error bars represent SEM (n = 3).
(C) N-terminal acetylation inhibits arginylation. Normalized incorporation of
[3H]-Arg into a synthetic peptide corresponding to the actin’s N terminus
(DDDIAALC) is greatly diminished after the N-terminal amino group of this
peptide is blocked by acetylation (AcDDDIAALC), despite the presence of
multiple side chain carboxyl groups. Error bars represent SEM (n = 3).
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minal amino group by acetylation in another actin-derived
peptide had a similar effect (Figure 2C). Thus, N-terminal arginy-
lation requires both the carboxy and the amino groups at the
target site.
N-Terminal Arginylation of the Peptide Substrates
Occurs by the Alpha Amino Group
To directly test which chemical group is involved in the final prod-
uct of the ATE1-1-mediated N-terminal arginylation, we analyzed
the in-vitro-arginylated peptide DDIAALVVDNGSGMCK (corre-
sponding to the N terminus of beta actin; Figure 2A) by subtrac-
tive Edman sequencing, measuring the mass of the remaining
peptide after each Edman cycle by MALDI-TOF. In this test,
the majority of the peptide behaved as expected for the conven-
tional Edman sequencing, releasing Arg in the first cycle (see Fig-
ure S2 for the peptide before and after the first Edman cycle).
This result was confirmed by conventional Edman sequencing,334 Chemistry & Biology 21, 331–337, March 20, 2014 ª2014 Elsevieconfirming that ATE1-mediated Arg linkage to the actin’s N-ter-
minal peptide in vitro occurred via the alpha amino group.
To further test whether N-terminal Arg-Asp linkage engages
the amino or carboxyl group of Arg (and, consequently, the
carboxy or amino group at the target Asp), we used nuclear mag-
netic resonance (NMR) to analyze the biological regulatory pep-
tide angiotensin II (DRVYIHPF), enzymatically arginylated with
isotopically labeled [13C,15N]-Arg. It has been previously shown
that angiotensin II is a good substrate for ATE1 in vitro and
accepts Arg on its N-terminal Asp (Soffer, 1975). This was
confirmed in our experiments (Figure 3A, left).
Comparison of the NMR analysis of highly arginylated
angiotensin II using ATE1-1 and [13C,15N]-Arg ([13C, 15N]-R-
DRVYIHPF) with the free [13C, 15N] Arg revealed that all the
carbon and nitrogen atoms from the isotopically labeled Arg in
free form or bound to angiotensin II were observed in proton-
detected 1H, 13C-HSQC and carbon-detected C-CAN and
C-CACO spectra (Figure 3A, right). The chemical shift analysis
showed that the backbone carbonyl carbon of arginylated Arg
exhibited the largest chemical shift (4.4 ppm) compared to that
of the free Arg, suggesting that the alpha carboxyl group of Arg
is unambiguously engaged in its linkage to the peptide, as appro-
priate for a conventional peptide bond.
Arginylation of a Test Protein Substrate Occurs Largely
by Carboxyl Groups
To test how Arg is linked to proteins rather than peptide sub-
strates, we used BSA as a test substrate, previously found argi-
nylated at two Asp residues: the N terminus, exposed by the
removal of the signal peptide, and at Asp 135 (Wang et al.,
2011). We used [14C]-Arg to arginylate BSA and to enable detec-
tion by autoradiography, and we treated such radioactively argi-
nylated BSAwith either aminopeptidase B (ApB), which removes
N-terminal Arg residues from the peptide chain, or carboxypepti-
dase B (CpB), which removes C-terminal Arg residues (Folk and
Gladner, 1958; Hirose et al., 2006). Addition of ApB to the arginy-
lated BSA did not result in detectable reduction of the radioactive
label (Figure 3B), despite the fact that the enzyme preparation
was highly active in colorimetric assays with its test substrate
(Figure S3). This observation indicates that themajority of arginy-
lation in BSA does not involve formation of a canonical peptide
bond with the N-terminal Asp. In contrast, addition of CpB re-
sulted in a marked removal of radioactivity from BSA without a
detectable reduction in the BSA protein level detectable by Coo-
massie blue staining (Figure 3B), although high concentrations of
CpBwere required. To characterize this further,we tested the dy-
namics of CpB-mediated Arg removal over time and its depen-
dence on the commercially available CpB inhibitor (CPBi). In
these assays, Arg removal from BSA progressed over time and
was completely abolished in the presence of CPBi, confirming
the specificity of this reaction (Figure 3C). Dearginylation by
CpBwasalsodosedependent (Figure3D). Theseassays strongly
suggest that ATE1-mediated arginylation of BSA occurred to
large extent via Arg addition to the side chain carboxylate groups.
DISCUSSION
Our data demonstrate that ATE1, during posttranslational argi-
nylation, can utilize a different type of chemical linkage of Argr Ltd All rights reserved
Figure 3. ATE1 Mediates Different Arg Linkage in Proteins and Peptides
(A) Left: normalized incorporation of [3H]-Arg into angiotensin II in vitro indicates that it is an efficient ATE1 target. Error bars represent SEM (n = 3). Middle: NMR
spectrogram of [13C,15N]-Arg linked to angiotensin II indicates a shift at the Arg alpha carbon atom, suggesting that this atom is engaged in the linkage to the
peptide via the ‘‘conventional’’ peptide bond. Mass shifts are shown in the table on the right.
(B) Coomassie-stained gel (top) and audioradiograph (bottom) of BSA, in vitro arginylated using [14C]-Arg, incubated for 30 min alone or in the presence of
aminopeptidase B (APB) or carboxypeptidase B (CPB) as indicated at the bottom.
(C) CPB-mediated dearginylation of BSA can be inhibited by CPBi. Coomassie-stained gel (top) and audioradiograph (bottom) of BSA, in vitro arginylated using
[14C]-Arg, incubated for increasing intervals of time alone or in the presence of CPBwith andwithout added inhibitor (CPBi). The chart on the right shows the levels
of radioactive label divided by BSA protein levels (quantified from gel scans) for each condition at each time point. Error bars represent SEM (n = 3).
(D) CPB-mediated dearginylation of BSA is dose dependent. Coomassie-stained gel (top) and audioradiograph (bottom) of BSA, in vitro arginylated using
[14C]-Arg, incubated with decreasing molar ratios of CPB to BSA as indicated.
(E) Proposed mechanisms for arginylation (see explanations in Results). Protein chains are denoted by freeform circles.
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and peptides, compared to the previously assumed exclusively
N-terminal linkage. Our analysis suggests that many proteins
in vivo use this type of Arg linkage, expanding the traditional
view that arginylation requires preproteolysis or the action of
Met-aminopeptidases to expose Asp and Glu for N-terminal tar-
geting by ATE1. This side chain modification carries a potentially
high and independent biological significance and implicates that
arginylation, like other regulatory modifications (e.g., protein
phosphorylation), can affect side chains of amino acid residues
within otherwise intact protein chains and thus can transiently
or stably modify these proteins’ structure and facilitate their bio-
logical functions.Chemistry & Biology 21, 3Our results suggest that ATE1 can mediate two different types
of chemical linkages to target residues in a protein, one via
the ‘‘conventional’’ N-terminal peptide bond and one via the
carboxyl group of the target residue, presumably linked to the
alpha amino group of Arg. While it is uncommon for one enzyme
to catalyze the formation of two such different bonds, the depen-
dence of arginylation on both the amino and carboxyl groups at a
target site suggests that both groups may be involved in the for-
mation of an intermediate during the arginylation reaction and/or
participate in ATE1-mediated recognition or catalysis. The for-
mation of an amide bond requires activation of the carboxylic
acid for attack by the amine nucleophile. A similar reaction is
likely utilized by the enzymes that catalyze glutamylation and31–337, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 335
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other proteins (Janke et al., 2005, 2008; Rogowski et al., 2009).
In the case of arginylation, Arg-tRNA provides the activated
carboxylate for ATE-catalyzed arginylation, bypassing the
requirement of this reaction for ATP (Wang et al., 2011). N-termi-
nal arginylation could involve direct attack of the free amino
group of an N-terminal Asp analogous to protein translation,
where the free amino group of the peptide attacks the activated
carboxyl group of Arg-tRNA (Figure 3E, left). However, this
mechanism cannot account for arginylation of internal Asp resi-
dues, which requires activation of the Asp b-carboxylate. There-
fore, we suggest an alternative mechanism whereby N-terminal
and side chain arginylation derive from a common intermediate.
In this mechanism, the b-carboxylate of Asp first attacks the
ester of Arg-tRNA, forming an anhydride intermediate wherein
both carboxylate groups are activated (Figure 3E, right). If the
Asp is at the N terminus of a peptide, this intermediate could
react with the free amino group to form a canonical peptide
bond, creating an N-terminal Arg (Figure 3E, top right). Alterna-
tively, if the Asp is internal, the intermediate would subsequently
react with the amino group of Arg to form a noncanonical peptide
bond with the side chain of Asp. Similar acyltransfer reactions
are found in intein reactions (Volkmann andMootz, 2013). The re-
sulting adduct would have a C-terminal Arg residue that can be
recognized by CpB, albeit with a noncanonical amide bond,
which would account for the requirement for high concentrations
of CpB.
A number of midchain arginylated proteins are involved in the
functioning of the actin cytoskeleton. It is possible that arginyla-
tion-dependent regulation of these proteins (predominantly
midchain) may facilitate a different biological role of ATE1 in
regulating protein-protein interactions and facilitating their
assembly and biological activity, in contrast to its previously
described role in the N-end rule pathway of protein degradation,
which is exclusive to N-terminal arginylation. We hypothesize
that these two types of Arg linkage lead to different types of
downstream effects of arginylation as a global biological regu-
lator. These possibilities constitute exciting directions of further
studies.
SIGNIFICANCE
Arginylation is an emerging posttranslational modification
mediated by Arg-tRNA-protein-transferase (ATE1), which
links Arg predominantly to the acidic residues, Asp and
Glu. Prior studies suggested that this linkage must be solely
N terminal, requiring prior proteolysis or action by Met-ami-
nopeptidases to expose the target residue in a protein chain
and leading to implications that intact proteins in vivo
cannot undergo arginylation. The present study shows that
many proteins in vivo are modified on the side chains of
Asp and Glu via an unconventional chemical linkage that uti-
lizes the carboxyl rather than the amino groups at the target
sites and thus does not require any prior preprocessing.
Furthermore, we show that this side chain reaction can be
mediated by ATE1 itself in the absence of cofactors and
that this reaction likely predominates during the arginylation
of proteins rather than peptide substrates. This finding ex-
pands the scope of reactions involving arginylation and336 Chemistry & Biology 21, 331–337, March 20, 2014 ª2014 Elseviedemonstrates a potential global mechanism of regulation
of intact proteins in vivo.
EXPERIMENTAL PROCEDURES
Escherichia coli Strains, Miscellaneous Reagents, and Animal Care
BL21-CodonPlus (DE3)-RIL and BL21(DE3) were purchased from Stratagene.
The recombinant mouse ATE1 isoforms and Escherichia coli Arginy-tRNA syn-
thetase were purified as previously described (Wang et al., 2011). The care and
treatment of mice were performed in accordance with the relevant National
Institutes of Health guidelines.
Peptides
Human angiotensin II (A9525) was purchased from Sigma; Acetylated and
nonacetylated actin N-terminal peptide were synthesized by Dr. Henry
Zebroski at the Rockefeller University Proteomics Resource Center; nonargi-
nylated long actin N-terminal peptide, DN, DN-Me, and DN-All were
synthesized by Genscript. The rest of the peptides used in this study were syn-
thesized by P.L.
In Vitro Arginylation of Peptides
In vitro arginylation reaction of peptides by ATE1 was modified from (Wang
et al., 2011). See Supplemental Experimental Procedures for further details.
MS and Database Searches
Sample preparation and MS/MS were performed as previously described
(Wong et al., 2007; Xu et al., 2009). See Supplemental Experimental Proce-
dures for further details.
NMR Experiments
All NMR spectra were recorded on a Bruker Avance II 600 MHz NMR spec-
trometer, equipped with a Bruker TCI triple resonance cryoprobe. All NMR
samples were prepared by dissolving the lyophilized compounds in a buffer
with 50 mM sodium phosphate, 50 mM NaCl, and pH 6.3. The concentrations
of the samples were around 0.5 mM. The spectra were recorded with Bruker
Topspin standard pulse sequences at 25C, and the spectra were processed
with Bruker Topspin software based on the manufacturer’s suggestions.
Statistical Analysis
Calculation of SD and SEM was based on Student’s t distribution.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, three tables, and one dataset and can be found with this article
online at http://dx.doi.org/10.1016/j.chembiol.2013.12.017.
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